In this issue of the EJNMMI, a study evaluating a promising new PET tracer for imaging prostate cancer (PCa), 68 Ga-PSMA (PSMA), is published [1]. The paper deals with a retrospective analysis in 37 patients with biochemical recurrence of PCa who underwent both 18 F-fluoromethylcholine (CHO) and PSMA PET/CT for the purpose of restaging. The aim of the study was to compare the diagnostic performance of the novel tracer with that of CHO. On a patient basis, the detection rates were 70.3 % and 86.5 % for CHO and PSMA, respectively. PSMA also showed a better performance at low PSA values. The authors conclude that PSMA PET/CT can detect PCa relapse and metastasis with significantly improved contrast when compared with CHO PET/CT. This advantage is related to higher tracer uptake by PCa lesions and low background signal, which allow the detection of small lymph node, bone and liver metastases. Although innovative and interesting, this study had some limitations: it was retrospective; few lesions were confirmed by histology; several criteria were used to validate the uptake areas; the results were compared against CHO PET/CT, which was considered as a standard even though this modality is not established; and, finally, the impact on patient management is not discussed.The limitations of the study preclude recommendation of this new radiopharmaceutical in oncological guidelines, a fate that has befallen many other promising PET tracers. This is a critical issue for the future of nuclear medicine and deserves a commentary. The way we introduce new radiopharmaceuticals into the clinical arena is highly influenced by published data and we believe that efforts are needed to enhance the impact of our reports in the world of oncology.Although many readers are well aware of PCa imaging, let us briefly summarize the state of the art of PET radiopharmaceuticals that are used to study PCa.PCa is a considerable health issue and has displayed an increasing incidence worldwide during the last decade [2] -a trend that justifies the burgeoning medical interest in this disease. We can say that PCa is studied as much in men as breast cancer is studied in, mostly, women. As always in oncology, accurate detection of disease spread is crucial for treatment decisions and imaging could play a major role in identifying tumour extension, provided that sufficient diagnostic accuracy is properly demonstrated. Of course, PET imaging is competing on many levels with other diagnostic modalities, but we will not cover these aspects. As a consequence of the great clinical interest in PCa, several PET radiopharmaceuti-